Tuesday's ETF Movers: SILJ, IHE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2025
0mins
Source: NASDAQ.COM
iShares U.S. Pharmaceuticals ETF Performance: The iShares U.S. Pharmaceuticals ETF is down approximately 2.1% in Tuesday afternoon trading, with Neumora Therapeutics and Eli Lilly experiencing declines of about 9.3% and 7.2%, respectively.
Market Commentary: The views expressed in the article reflect the author's opinions and do not necessarily represent those of Nasdaq, Inc.
Analyst Views on IHE
Wall Street analysts forecast IHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IHE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 87.100
Low
Averages
High
Current: 87.100
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
